Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-17-0284
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

The Efficacy of YKL-40 and CA125 as Biomarkers for Epithelial Ovarian Cancer

Brazilian Journal of Medical and Biological Research
ImmunologyCell BiologyPharmacologyBiochemistryBiophysicsNeuroscienceMedicineToxicologyPhysiologyPharmaceutics
2010English

Preclinical Immunotherapy With Cytokine-Induced Killer Lymphocytes Against Epithelial Ovarian Cancer

Scientific Reports
Multidisciplinary
2020English

The Use of HE4, CA125 and CA72-4 Biomarkers for Differential Diagnosis Between Ovarian Endometrioma and Epithelial Ovarian Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2013English

TP53 Mutations Are Immunogenic in Epithelial Cancer

Cancer Discovery
Oncology
2019English

The Clinical Correlates of Serum CA125 in 169 Patients With Epithelial Ovarian Carcinoma

British Journal of Cancer
Cancer ResearchOncology
1989English

Predictors of Pretreatment CA125 at Ovarian Cancer Diagnosis: A Pooled Analysis in the Ovarian Cancer Association Consortium

Cancer Causes and Control
Cancer ResearchOncology
2017English

NuMA Overexpression in Epithelial Ovarian Cancer

PLoS ONE
Multidisciplinary
2012English

Ovarian Cancer Animal Models for Preclinical Studies and Development of Ovarian Cancer Drugs

JURNAL ILMU KEFARMASIAN INDONESIA
2019English

Chronic Medical Conditions and CA125 Levels Among Women Without Ovarian Cancer

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy